Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Alfasigma set to purchase Intercept Pharmaceuticals at $19.00 each stock in cash, broadening international reach in unusual and critical liver ailments
Latest Hotspot
3 min read
Alfasigma set to purchase Intercept Pharmaceuticals at $19.00 each stock in cash, broadening international reach in unusual and critical liver ailments
8 October 2023
Intercept's principal drug is Ocaliva® (obeticholic acid), an FDA-approved farnesoid X receptor agonist in the United States and numerous other regions.
Read →
An In-depth Analysis of Flutamide's R&D Progress and Mechanism of Action on Drug Target
Drug Insights
4 min read
An In-depth Analysis of Flutamide's R&D Progress and Mechanism of Action on Drug Target
8 October 2023
This article summarized the latest R&D progress of Flutamide, the Mechanism of Action for Flutamide, and the drug target R&D trends for Flutamide.
Read →
Gracell Biotechnologies starts dosing in US Phase 1b/2 trial assessing GC012F's efficacy for treating recurrent or resistant multiple myeloma
Latest Hotspot
3 min read
Gracell Biotechnologies starts dosing in US Phase 1b/2 trial assessing GC012F's efficacy for treating recurrent or resistant multiple myeloma
8 October 2023
Gracell Biotechnologies Inc. has announced that the initial patient in the US has begun treatment in a Phase 1b/2 clinical trial for it's foremost candidate, GC012F, targeting patients with recurrent or resistant multiple myeloma.
Read →
Flunisolide: Detailed Review of its Transformative R&D Success, Mechanism of Action, and Drug Target
Drug Insights
4 min read
Flunisolide: Detailed Review of its Transformative R&D Success, Mechanism of Action, and Drug Target
7 October 2023
This article summarized the latest R&D progress of Flunisolide, the Mechanism of Action for Flunisolide, and the drug target R&D trends for Flunisolide.
Read →
Adverum Biotechnologies reported encouraging Aflibercept Protein level results from their LUNA Phase 2 study
Latest Hotspot
3 min read
Adverum Biotechnologies reported encouraging Aflibercept Protein level results from their LUNA Phase 2 study
7 October 2023
Adverum Biotechnologies has released early findings on aflibercept protein activity from its ongoing Phase 2 LUNA study.
Read →
Fenofibric acid Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs, Mechanisms of Action, and Drug Target
Drug Insights
4 min read
Fenofibric acid Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs, Mechanisms of Action, and Drug Target
5 October 2023
This article summarized the latest R&D progress of Fenofibric acid, the Mechanism of Action for Fenofibric acid, and the drug target R&D trends for Fenofibric acid.
Read →
Smart Immune begins administering its ProTcell Therapy SMART101 to leukemia patients in the ReSET-02 Phase I/II study
Latest Hotspot
3 min read
Smart Immune begins administering its ProTcell Therapy SMART101 to leukemia patients in the ReSET-02 Phase I/II study
5 October 2023
Two patients have been administered the initial dosage of SMART101, an allogeneic cell therapy created from donor mobilized peripheral blood stem cells which have been converted into T-cell progenitors utilizing the ProTcell treatment platform by Smart Immune.
Read →
Unleashing the Power of Eletriptan hydrobromide: A Comprehensive Review on R&D Breakthroughs, Action Mechanisms, and Drug Target
Drug Insights
4 min read
Unleashing the Power of Eletriptan hydrobromide: A Comprehensive Review on R&D Breakthroughs, Action Mechanisms, and Drug Target
5 October 2023
This article summarized the latest R&D progress of Eletriptan hydrobromide, the Mechanism of Action for Eletriptan hydrobromide, and the drug target R&D trends for Eletriptan hydrobromide.
Read →
miRNA and Disease Regulation
Advanced Tech.
4 min read
miRNA and Disease Regulation
5 October 2023
miRNA is an endogenous tiny non-coding RNA, generally 21-23 nucleotides long, with the function of regulating gene expression at the translational level.
Read →
 A Comprehensive Review of Efavirenz's R&D Innovations and Drug Target Mechanism
Drug Insights
4 min read
A Comprehensive Review of Efavirenz's R&D Innovations and Drug Target Mechanism
5 October 2023
This article summarized the latest R&D progress of Efavirenz, the Mechanism of Action for Efavirenz, and the drug target R&D trends for Efavirenz.
Read →
Ionis reports positive early results from Phase 3 trial of Olezarsen for familial chylomicronemia syndrome patients
Latest Hotspot
3 min read
Ionis reports positive early results from Phase 3 trial of Olezarsen for familial chylomicronemia syndrome patients
5 October 2023
Ionis declared encouraging preliminary findings from Phase 3 trial of Olezarsen in patients suffering from familial chylomicronemia syndrome.
Read →
Pharmaceutical Insights: Torsemide's R&D Progress and its Mechanism of Action on Drug Target
Drug Insights
4 min read
Pharmaceutical Insights: Torsemide's R&D Progress and its Mechanism of Action on Drug Target
5 October 2023
This article summarized the latest R&D progress of Torsemide, the Mechanism of Action for Torsemide, and the drug target R&D trends for Torsemide.
Read →